NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 240 filers reported holding NEKTAR THERAPEUTICS in Q3 2021. The put-call ratio across all filers is 0.30 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $297 | +3.5% | 500 | 0.0% | 0.00% | – |
Q2 2023 | $287 | -18.2% | 500 | 0.0% | 0.00% | – |
Q1 2023 | $351 | -68.9% | 500 | 0.0% | 0.00% | – |
Q4 2022 | $1,130 | +13.0% | 500 | 0.0% | 0.00% | – |
Q3 2022 | $1,000 | 0.0% | 500 | 0.0% | 0.00% | – |
Q2 2022 | $1,000 | -50.0% | 500 | 0.0% | 0.00% | – |
Q1 2022 | $2,000 | -66.7% | 500 | 0.0% | 0.00% | – |
Q4 2021 | $6,000 | -25.0% | 500 | 0.0% | 0.00% | – |
Q3 2021 | $8,000 | 0.0% | 500 | 0.0% | 0.00% | – |
Q2 2021 | $8,000 | -72.4% | 500 | -16.7% | 0.00% | – |
Q2 2018 | $29,000 | -54.0% | 600 | 0.0% | 0.00% | – |
Q1 2018 | $63,000 | – | 600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |